lilly retatrutide Lilly's Retatrutide: Toward the End of Incremental Metabolic Medicine Eli Lilly’s Phase 3 data

This approach can be considered for stable, tolerating patients where risk of heightened side effects is judged by the clinician to be low

This reduces data noise and protects research validity

Treatment should be discontinued after 12 weeks if patients have not lost at least 5% of their initial body weight

That means counting precise calories or macros rather than just, say, following a Mediterranean diet

You receive a detailed report of your body composition: your total body fat percentage, total fat mass in pounds (or kg), total lean mass, and bone mineral content

KEY TAKEAWAY: Months 7-11 represent the new normal